Capra Maria Elena, Biasucci Giacomo, Banderali Giuseppe, Vania Andrea, Pederiva Cristina
Centre for Pediatric Dyslipidemias, Pediatrics and Neonatology Unit, University of Parma, Guglielmo da Saliceto Hospital, 29121 Piacenza, Italy.
Department of Translational Medical and Surgical Sciences, University of Parma, 43126 Parma, Italy.
Children (Basel). 2024 Feb 15;11(2):250. doi: 10.3390/children11020250.
Familial hypercholesterolemia is a genetically determined disease characterized by elevated plasma total and LDL cholesterol levels from the very first years of life, leading to early atherosclerosis. Nutritional intervention is the first-line treatment, complemented with nutraceuticals and drug therapy when necessary. Nutraceuticals with a lipid-lowering effect have been extensively studied in the past few decades, and have been recently included in international guidelines as a complement to nutritional and pharmacological treatment in subjects with dyslipidemia. In this review, we explore current nutritional interventions for dyslipidemia in childhood, with a specific focus on the main nutraceuticals studied for treating severe dyslipidemia in pediatric patients. Additionally, we briefly describe their primary mechanisms of action and highlight the advantages and risks associated with the use of lipid-lowering nutraceuticals in childhood.
家族性高胆固醇血症是一种由基因决定的疾病，其特征是从生命的最初几年起血浆总胆固醇和低密度脂蛋白胆固醇水平升高，导致早期动脉粥样硬化。营养干预是一线治疗方法，必要时辅以营养保健品和药物治疗。在过去几十年中，对具有降脂作用的营养保健品进行了广泛研究，最近已被纳入国际指南，作为血脂异常患者营养和药物治疗的补充。在这篇综述中，我们探讨了目前儿童血脂异常的营养干预措施，特别关注用于治疗儿科患者严重血脂异常的主要营养保健品。此外，我们简要描述了它们的主要作用机制，并强调了儿童使用降脂营养保健品的优点和风险。
